Financiere de Tubize SA banner

Financiere de Tubize SA
XBRU:TUB

Watchlist Manager
Financiere de Tubize SA Logo
Financiere de Tubize SA
XBRU:TUB
Watchlist
Price: 204.2 EUR -2.95% Market Closed
Market Cap: €9.1B

TUB's latest stock split occurred on Jun 17, 2005

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on Jun 17, 2005. This was TUB's 2nd stock split, following the previous one in Nov 26, 1999.

Last Splits:
Jun 17, 2005
2-for-1
Nov 26, 1999
100-for-1
Pre-Split Price
N/A
Post-Split Price
29.8235
Before
After
Last Splits:
Jun 17, 2005
2-for-1
Nov 26, 1999
100-for-1

Financiere de Tubize SA
Stock Splits History

TUB Stock Splits Timeline
Jun 17, 2005
Jun 17, 2005
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
29.8235
Before
After
Nov 26, 1999
Nov 26, 1999
Split 100-for-1
x100
Pre-Split Price
N/A
Post-Split Price
29.8235
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 24, 2026
Cue Biopharma Inc
NASDAQ:CUE
1-for-30
/30
0.5542 16.626 USD 17.695 17.695 USD
Apr 24, 2026
Medical Data Vision Co Ltd
TSE:3902
2-for-7253607
/3626803.5
1684 1684 JPY N/A
Apr 24, 2026
E
ESGL Holdings Ltd
NASDAQ:ESGL
1-for-3
/3
2.35 7.05 USD 2.93 2.93 USD
Apr 24, 2026
Metro Mining Ltd
ASX:MMI
1-for-20
/20
0.067 1.34 AUD 1.3 1.3 AUD
Apr 24, 2026
L
La Comer SAB de CV
OTC:LCMRF
115-for-114
x1.0087719298246
2.4715 2.4341 USD 2.45 2.45 USD
Load More

Financiere de Tubize SA
Glance View

Market Cap
9.1B EUR
Industry
Pharmaceuticals

Nestled in the heart of Belgium, Financiere de Tubize SA stands as a distinctive player in the world of investment holding companies, anchored in its robust shareholding strategy. Unlike many investment entities that diversify their portfolios across industries, Tubize has channeled its focus largely into the pharmaceutical sector through its significant shareholding in UCB, a global biopharmaceutical giant. This singular focus reflects a strategic commitment to capitalize on the growth and innovations within the healthcare industry, leveraging UCB's extensive research capabilities and expansive market presence. By holding a concentrated position in a company with established credentials in developing treatments for severe diseases, Tubize essentially acts as a conduit for investors to gain exposure to the burgeoning potential of biopharmaceutical advancements. The financial success of Financiere de Tubize SA is intricately tied to the performance of UCB. As UCB thrives and expands through its innovative drug developments and strategic market expansions, Tubize enjoys a consistent flow of dividends and capital appreciation. This dividend income underpins Tubize's operational model, allowing it to reinvest in its core holdings and distribute earnings to its own shareholders, thereby creating a cyclical flow of wealth generation and sustainability. Tubize's approach is akin to a watchful guardian, closely monitoring UCB's strategic paths while maintaining an investment structure that keeps administrative and operational costs minimal. Through such a streamlined focus, Financiere de Tubize SA offers investors a targeted and long-term pathway into the pharmaceutical sector, marked by careful oversight and strategic clarity.

TUB Intrinsic Value
22.07 EUR
Overvaluation 89%
Intrinsic Value
Price €204.2
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett